An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo
Figure 7
rhArg-Fc inhibits tumor growth in vivo. (a) 106 Huh7 cells were injected s.c. into the 4-week-old nude mice. The rhArg-Fc treatments were initiated after the size of the tumor reached approximately 5–10 mm in diameter. Six animals were used for each treatment group (cisplatin 0.5 mg/kg or rhArg-Fc 300 IU/mouse or a combination of both treatments). The tumor size was monitored every 5 days for 50 days. (b) 105 Huh7 were treated with 0.2 μg/mL cisplatin in the presence or absence of 0.5 IU/mL rhArg-Fc. After 3 days, the number of cells was determined by MTT assay.
